ReP USP - Resultado da busca

Filtros : "Kantoff, Philip W." Limpar

Filtros

Collaboration
Normalized affiliation
Non normalized affiliation
- brigham and women's hospital and dana farber cancer institute - department of medicine - boston, ma, usa (1)
- brigham and women's hospital and dana farber cancer institute - department of radiation oncology - boston, ma, usa (1)
- department of medical oncology and radiation oncology - dana-farber cancer institute and brigham and women's hospital - boston, massachusetts (1)
- department of statistics - university of connecticut - storrs, connecticut (1)
- harvard radiation oncology program - harvard medical school - boston, massachusetts (1)

Artigo de periodico
Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial (2013)
Kim, Miranda B.; Chen, Ming-Hui; Castro, Mário de ; Loffredo, Marian; Kantoff, Philip W.; D'Amico, Anthony Victor
Source: Cancer. Unidade: ICMC
Subjects: INFERÊNCIA BAYESIANA, ESTATÍSTICA APLICADA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KIM, Miranda B. et al. Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial. Cancer, v. 119, n. 18, p. 3280\20133286, 2013Tradução . . Disponível em: https://doi.org/10.1002/cncr.28202. Acesso em: 02 maio 2024.
APA
Kim, M. B., Chen, M. -H., Castro, M. de, Loffredo, M., Kantoff, P. W., & D'Amico, A. V. (2013). Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial. Cancer, 119( 18), 3280\20133286. doi:10.1002/cncr.28202
NLM
Kim MB, Chen M-H, Castro M de, Loffredo M, Kantoff PW, D'Amico AV. Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial [Internet]. Cancer. 2013 ; 119( 18): 3280\20133286.[citado 2024 maio 02 ] Available from: https://doi.org/10.1002/cncr.28202
Vancouver
Kim MB, Chen M-H, Castro M de, Loffredo M, Kantoff PW, D'Amico AV. Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial [Internet]. Cancer. 2013 ; 119( 18): 3280\20133286.[citado 2024 maio 02 ] Available from: https://doi.org/10.1002/cncr.28202
Artigo de periodico
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials (2012)
D'Amico, Anthony Victor; Chen, Ming-Hui; Castro, Mário de ; Loffredo, Marian; Lamb, David S.; Steigler, Allison; Kantoff, Philip W.; Denham, James W.
Source: The Lancet Oncology. Unidade: ICMC
Subjects: INFERÊNCIA BAYESIANA, ESTATÍSTICA APLICADA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
D'AMICO, Anthony Victor et al. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. The Lancet Oncology, v. 13, n. 2, p. 189-195, 2012Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(11)70295-9. Acesso em: 02 maio 2024.
APA
D'Amico, A. V., Chen, M. -H., Castro, M. de, Loffredo, M., Lamb, D. S., Steigler, A., et al. (2012). Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. The Lancet Oncology, 13( 2), 189-195. doi:10.1016/S1470-2045(11)70295-9
NLM
D'Amico AV, Chen M-H, Castro M de, Loffredo M, Lamb DS, Steigler A, Kantoff PW, Denham JW. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials [Internet]. The Lancet Oncology. 2012 ; 13( 2): 189-195.[citado 2024 maio 02 ] Available from: https://doi.org/10.1016/S1470-2045(11)70295-9
Vancouver
D'Amico AV, Chen M-H, Castro M de, Loffredo M, Lamb DS, Steigler A, Kantoff PW, Denham JW. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials [Internet]. The Lancet Oncology. 2012 ; 13( 2): 189-195.[citado 2024 maio 02 ] Available from: https://doi.org/10.1016/S1470-2045(11)70295-9

Digital Library of Intellectual Production of Universidade de São Paulo 2012 - 2024